Hubei Goto Biopharm News

Kyodo Pharmaceutical (300966): Q3 revenue and performance are in line with market expectations and large-scale production capacity is being launched one after another

The Pacific SecuritiesOct 24 00:00

Kyodo Pharmaceutical (300966): Q2 performance is slightly lower than market expectations, production capacity investment in the second half of the year is expected to help rapid revenue growth

Aug 28 00:00

Kyodo Pharmaceutical (300966): Q1 performance is in line with market expectations, product price increases, and gross profit margin increases

Apr 26 10:11

Pacific released a research report on April 14 stating that Kyodo Pharmaceutical (300966.SZ) was given an increase in holdings rating. The main reasons for the rating include: 1) being deeply involved in the steroidal drug field for nearly 20 years, layin

Zhitong FinanceApr 14 10:06

Kyodo Pharmaceutical (300966): Focus on expanding products in the field of steroidal drugs downstream to open up room for growth

Apr 11 00:00